Form 4 for CRVO CervoMed Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-13 · accession 0001437749-25-035309 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-11-17 | 2025-11-14 | CRVO | ALAM JOHN J | CEO, Pres, Dir, 10% | P - Purchase | $7.57 | +1,707 | 1,707 | New | +$12.9K |
| M | 2025-11-17 | 2025-11-13+ | CRVO | ALAM JOHN J | CEO, Pres, Dir, 10% | P - Purchase | $7.52 | +6,140 | 1.47M | +0.4% | +$46.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-14 | P | A | 1,707 | $7.57 | 1,707 | I | — | — | (F1) Shares purchased in open-market transactions. (F4) Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. |
| 2 | Common | Common Stock | 2025-11-14 | P | A | 1,693 | $7.55 | 1,473,271 | D | — | — | (F1) Shares purchased in open-market transactions. (F3) Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. (F2) Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. |
| 3 | Common | Common Stock | 2025-11-13 | P | A | 4,447 | $7.51 | 1,471,578 | D Spouse's IRA | — | — | (F1) Shares purchased in open-market transactions. (F2) Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. (F4) Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. |